Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis Pharma AG
Woman and Man Max 99 years
Novartis Pharma AG
Update Il y a 4 ans
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2000 mg/d as adjunctive therapy to lithium or valproate in the treatment of manic episodes of bipolar I disorder over 6 weeks
To demonstrate the efficacy of licarbazepine 750-2000 mg/d added to lithium or valproate in the treatment of manic episodes of bipolar I disorder by testing the following hypothesis: Licarbazepine ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma AG
Update Il y a 4 ans
Et randomiseret, dobbeltblindet placebo kontrolleret, add-on forsøg til vurdering af effekten af peroral aliskiren 300 mg én gang dagligt til behandling af diabetisk makulaødem
To assess the effect of aliskiren compared to placebo on change in central retina thickness (CRT), measured by optical coherence tomography (OCT), from the baseline thickness in patients with type 1 ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma AG
Update Il y a 4 ans
A Phase II, double-blind, randomized, Proof-of-Concept, dose-ranging trial evaluating the efficacy, safety and pharmacokinetics of oral LDE225 in treatment of adult patients with Nevoid Basal Cell Carcinoma Syndrome
•To evaluate the efficacy of LDE225, as assessed by clinical clearance of a main target BCC (one per patient) in Nevoid Basal Cell Carcinoma Syndrome (NBCCS) patients
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma AG
Update Il y a 4 ans
Dose response study of EMA401 in patients with post-herpetic neuralgia (PHN)
To characterize dose response, and evaluate safety and efficacy of three different doses of EMA401 compared to placebo in patients with post-herpetic neuralgia (PHN)
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma AG
Update Il y a 4 ans
An international, multicenter, randomized, open-label, safety and efficacy trial of intravenous zoledronic acid administered either once or twice yearly in children with severe osteogenesis imperfecta, a 1-year extension to CZOL446H2202
to examine the long-term safety of two different dosage regiments of zoledronic acid over an additional 12 months in pediatric patients who have completed one-year of treatment of zoledronic acid in t...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma AG
Update Il y a 4 ans
A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose study to assess the efficacy and tolerability of AFQ056 in reducing L-dopa induced dyskinesias in Parkinson’s patients with severe motor complications
•To assess the potential anti-dyskinetic efficacy of multiple titrated doses of AFQ056 in Parkinson’s patients with severe L-dopa induced dyskinesias using the Abnormal Involuntary Movement Scale (AIM...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma AG
Update Il y a 4 ans
A randomized, double-blind, placebo-controlled, 2-period, cross-over study to assess the efficacy and safety of differing doses of NVA237 administered either once daily or twice daily, in patients with moderate to severe chronic obstructive pulmonary disease (COPD)
To evaluate the relationship of incremental doses of NVA237 q.d. and b.i.d. and their effect on trough FEV1 after 28 days of treatment, as defined by the percentage of the maximal effect that each dos...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma AG
Update Il y a 4 ans
Compare the efficacy and assess the safety of secukinumab given as 3 intravenous (i.v.) loading doses or weekly sub-cutaneous (s.c.) loading doses, compared to placebo, followed by monthly s.c. injections in patients with active Rheumatoid Arthritis despite treatment with methotrexate
To demonstrate the superior efficacy of secukinumab administered during induction with an i.v. loading regimen or a s.c. loading dose regimen compared to placebo in patients with active rheumatoid art...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma AG
Update Il y a 4 ans
A randomized, double-blind, multicenter, active-controlled, parallel design trial to evaluate the safety and efficacy of the combination of valsartan/amlodipine 160/5 mg or 160/10 mg versus valsartan 160 mg alone for 8 weeks in hypertensive patients who are not adequately controlled on valsartan 160 mg monotherapy
To demonstrate the efficacy of the combinations of valsartan/amlodipine 160/10 or 160/5 mg, in patients with essential hypertension not adequately controlled on valsartan 160 mg monotherapy, by testin...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma AG
Update Il y a 4 ans
13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson’s disease
To demonstrate the anti-dyskinetic efficacy, as measured by change from baseline to endpoint at week 12 in the modified AIMS (Abnormal Involuntary Movement Scale) total score, of five fixed doses of A...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
Next